South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.

Though Samsung Biologics and its labor union, which previously failed to reach an agreement despite government mediation, have decided to return to direct negotiations, signs are emerging that the ...

Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG ("PolyPeptide") (ISIN ...

Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its mult ...

Add Yahoo as a preferred source to see more of our stories on Google. Samsung Biologics will conduct a simulated outbreak response using wild-type H5 influenza as a prototype pathogen The Coalition ...

Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.

With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Samsung has locked down a $1.2 billion contract with an unnamed Asia-based ...

The supply contracts are piling up over at Samsung Biologics. Within mere days, the South Korean company has rung up roughly $1.5 billion worth of manufacturing orders from the likes of Pfizer and ...

After the Incheon Regional Labor Relations Commission ruled in Case No. Incheon 2025 Discrimination 10 that the exclusion of contract workers from holiday gift benefits constituted discriminatory ...

Samsung Biologics signed a deal with an unnamed U.S.-based pharma company worth up to $1.05 billion, according to a recent public disclosure. It’s the largest contract manufacturing (CMO) agreement ...

South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug ...